NASDAQ:ZFGN Zafgen Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Zafgen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $15.82 -0.69 (-4.18 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$15.79Now: $15.82▼$16.6950-Day Range$0.99MA: $12.09▼$17.6052-Week Range$0.62Now: $15.82▼$2.76Volume237,718 shsAverage Volume360,199 shsMarket Capitalization$592.78 millionP/E RatioN/ADividend YieldN/ABeta0.27 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.Read More Beat the Market (BTM) Rank™ 1.0 Analyst's Opinion Consensus RatingZafgen has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $0.78, Zafgen has a forecasted downside of 95.1% from its current price of $15.82.Amount of Analyst CoverageZafgen has received no research coverage in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesZafgen has received 345 “outperform” votes. (Add your “outperform” vote.)Underperform VotesZafgen has received 316 “underperform” votes. (Add your “underperform” vote.)Community SentimentZafgen has received 52.19% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Zafgen and other stocks. Vote “Outperform” if you believe ZFGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ZFGN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldZafgen does not currently pay a dividend.Dividend GrowthZafgen does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zafgen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 14.20% of the stock of Zafgen is held by insiders.Percentage Held by Institutions70.43% of the stock of Zafgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Zafgen is -16.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zafgen is -16.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZafgen has a P/B Ratio of 11.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.92 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ZFGN Previous Symbol CUSIPN/A CIK1374690 Webwww.zafgen.com Phone617-622-4003Debt Debt-to-Equity Ratio0.26 Current Ratio6.56 Quick Ratio6.56Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.35 per share Price / Book11.72Profitability EPS (Most Recent Fiscal Year)($1.07) Net Income$-45,410,000.00 Net MarginsN/A Return on Equity-51.34% Return on Assets-34.55%Miscellaneous Employees38 Outstanding Shares37,470,000Market Cap$592.78 million Next Earnings DateN/A OptionableOptionable $15.82 -0.69 (-4.18 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ZFGN News and Ratings via Email Sign-up to receive the latest news and ratings for ZFGN and its competitors with MarketBeat's FREE daily newsletter. Zafgen (NASDAQ:ZFGN) Frequently Asked Questions How has Zafgen's stock been impacted by Coronavirus (COVID-19)? Zafgen's stock was trading at $0.8501 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ZFGN stock has increased by 1,761.0% and is now trading at $15.82. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Zafgen? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zafgen in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Zafgen. How were Zafgen's earnings last quarter? Zafgen Inc (NASDAQ:ZFGN) released its earnings results on Thursday, March, 5th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.19). View Zafgen's earnings history. What price target have analysts set for ZFGN? 1 Wall Street analysts have issued 1-year price targets for Zafgen's stock. Their forecasts range from $0.78 to $0.78. On average, they expect Zafgen's share price to reach $0.78 in the next year. This suggests that the stock has a possible downside of 95.1%. View analysts' price targets for Zafgen. Who are some of Zafgen's key competitors? Some companies that are related to Zafgen include Karuna Therapeutics (KRTX), Aimmune Therapeutics (AIMT), Taro Pharmaceutical Industries (TARO), Opko Health (OPK), Intra-Cellular Therapies (ITCI), Revance Therapeutics (RVNC), I-Mab (IMAB), Corcept Therapeutics (CORT), Zymeworks (ZYME), Humanigen (HGEN), Eidos Therapeutics (EIDX), CytoDyn (CYDY), Myovant Sciences (MYOV), Aurinia Pharmaceuticals (AUPH) and Seres Therapeutics (MCRB). View all competitors. What other stocks do shareholders of Zafgen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zafgen investors own include SCYNEXIS (SCYX), CA (CA), Endologix (ELGX), Energy Transfer LP Unit (ET), TG Therapeutics (TGTX), BlackRock (BLK), Fate Therapeutics (FATE), Pfizer (PFE), Spectrum Pharmaceuticals (SPPI) and Esperion Therapeutics (ESPR). Who are Zafgen's key executives? Zafgen's management team includes the following people: Mr. Jeffrey S. Hatfield, CEO & Director (Age 61)Ms. Patricia L. Allen, Chief Financial Officer (Age 57)Dr. Dennis D. Kim M.D., MBA, Chief Medical Officer (Age 49)Dr. James E. Vath, Head of Discovery & Devel. (Age 58)Mr. Brian P. McVeigh, Chief Bus. Officer (Age 46) What is Zafgen's stock symbol? Zafgen trades on the NASDAQ under the ticker symbol "ZFGN." How do I buy shares of Zafgen? Shares of ZFGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Zafgen's stock price today? One share of ZFGN stock can currently be purchased for approximately $15.82. How big of a company is Zafgen? Zafgen has a market capitalization of $592.78 million. The biopharmaceutical company earns $-45,410,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Zafgen employs 38 workers across the globe. What is Zafgen's official website? The official website for Zafgen is www.zafgen.com. How can I contact Zafgen? Zafgen's mailing address is 3 Center Plaza Suite 610, BOSTON MA, 02108. The biopharmaceutical company can be reached via phone at 617-622-4003 or via email at [email protected] This page was last updated on 9/19/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
